Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Keratinocyte Growth Factor Clear all

Conditions: WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, Myelokathexis
Interventions: Busulfan, Palifermin, Plerixafor, Filgrastim, Base-edited hematopoietic stem and progenitor cells; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Plasma Cell Leukemia in Remission, Plasma Cell Myeloma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim, Laboratory Biomarker Analysis, Lenalidomide, pheresis, Melphalan, Palifermin, Total Marrow Irradiation; Procedure · Drug · Biological + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Duarte, California

Conditions: Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes
Interventions: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
Interventions: filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 12 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma
Interventions: Gemcitabine, Busulfan, Melphalan, Stem Cell Transplantation, Palifermin; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Palifermin, Palifermin placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 22
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 15 more

Conditions: X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions: Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells; Genetic · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 99 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Interventions: Palifermin; Drug
Lead sponsor: Brett King; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Bridgeport, Connecticut • New Haven, Connecticut

Conditions: Graft-vs-Host Disease
Interventions: Recombinant Human Keratinocyte Growth Factor (rHuKGF); Drug
Lead sponsor: FDA Office of Orphan Products Development; Federal
Eligibility: 3 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions: Palifermin, Lupron, peripheral blood stem cell transplantation, Total-Body Irradiation (TBI), Thiotepa, Cyclophosphamide, Degarelix; Biological · Procedure · Radiation + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Myeloma
Interventions: Palifermin, Dexamethasone, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant, G-CSF; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Hematopoietic Cell Transplantation Recipient
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide, Goat Milk, Laboratory Biomarker Analysis, Palifermin, Sirolimus, Tacrolimus, Total-Body Irradiation; Procedure · Drug · Other + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 12 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions: palifermin, cisplatin, placebo, neck dissection, radiation therapy; Biological · Drug · Other + 2 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 47
States / cities: Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more

Conditions: Alopecia, Chemotherapy-Induced Change, Hair Loss, Alopecia Drugs
Interventions: Keratinocyte growth factor; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: T-cell Non-Hodgkin Lymphoma
Interventions: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Leukemia
Interventions: Palifermin, Total Body irradiation, Chemotherapy; Drug · Radiation
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: Tucson, Arizona • Loma Linda, California • Los Angeles, California + 3 more

Search by objective public record fields.

Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Keratinocyte Growth Factor to Prevent Acute GVHD

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT